Goodrx (GDRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.08
- EPS estimate
- $0.08
- EPS surprise
- +0.38%
- Revenue surprise
- +3.72%
- Revenue
- $200.4M
- Revenue estimate
- $193.2M
- Reported
- Aug 5, 2026
GoodRx reported Q2 2026 results on August 5, 2026. EPS was $0.08, a hair above the $0.08 estimate, with a surprise of 0.38%. Revenue was $200.4 million, above the $193.2 million consensus. Compared with Q2 2025, EPS slipped from $0.09 and revenue dipped 1.3% from $203.1 million.
The table shows a business with very stable results. Quarterly revenue has stayed between $180.0 million and $213.3 million throughout, and EPS between $0.06 and $0.10. Annual EPS was $0.30 in 2022, $0.28 in 2023, $0.33 in 2024 and $0.35 in 2025. Annual revenue moved in a narrow band, from $750.3 million to $796.9 million. First-half 2026 revenue of $394.4 million was about 2.9% below the same period of 2025. Every quarter was profitable. GoodRx beat EPS estimates in 11 of 20 quarters, but Q2 2026 ended a run of eight straight misses. Revenue topped the consensus 15 times.
Third-quarter results came between November 4 and November 10 in each of the past five years. That points to early November 2026 for the next report, which will show whether revenue returns to year-over-year growth.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.08 | $0.08 | +0.38% | $200.4M | SEC |
| Q1 2026 | May 6, 2026 | $0.07 | $0.07 | −2.64% | $194.0M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.09 | $0.09 | −1.75% | $194.8M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.09 | $0.08 | −11.41% | $196.0M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.10 | $0.09 | −9.09% | $203.1M | SEC |
| Q1 2025 | May 7, 2025 | $0.10 | $0.09 | −5.36% | $203.0M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.09 | $0.09 | −1.32% | $198.6M | SEC |
| Q3 2024 | Nov 7, 2024 | $0.09 | $0.08 | −7.94% | $195.3M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.09 | $0.08 | −8.05% | $200.6M | SEC |
| Q1 2024 | May 9, 2024 | $0.08 | $0.08 | +5.54% | $197.9M | SEC |
| Q4 2023 | Feb 29, 2024 | $0.07 | $0.08 | +18.52% | $196.6M | SEC |
| Q3 2023 | Nov 9, 2023 | $0.06 | $0.06 | +3.27% | $180.0M | SEC |
| Q2 2023 | Aug 9, 2023 | $0.06 | $0.07 | +15.70% | $189.7M | SEC |
| Q1 2023 | May 10, 2023 | $0.06 | $0.07 | +25.22% | $184.0M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.05 | $0.07 | +52.17% | $184.1M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.04 | $0.07 | +65.09% | $187.3M | SEC |
| Q2 2022 | Aug 8, 2022 | $0.04 | $0.06 | +52.28% | $191.8M | SEC |
| Q1 2022 | May 9, 2022 | $0.08 | $0.10 | +22.40% | $203.3M | SEC |
| Q4 2021 | Feb 28, 2022 | $0.10 | $0.09 | −9.00% | $213.3M | SEC |
| Q3 2021 | Nov 10, 2021 | $0.09 | $0.09 | +3.21% | $195.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Goodrx (GDRX) last report earnings?
Goodrx last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did GDRX beat earnings estimates?
Yes. Goodrx reported EPS of $0.08 for Q2 2026 against a $0.08 estimate — a 0.38% beat.
How much revenue did GDRX report last quarter?
Goodrx reported $200.4M in revenue for Q2 2026, against a consensus estimate of $193.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.